Analystreport

Health Catalyst, Inc. (NASDAQ: HCAT) had its "buy" rating re-affirmed by analysts at Raymond James. They now have a $66.00 price target on the stock.

Health Catalyst, Inc - Common stock  (HCAT) 
Last health catalyst, inc - common stock earnings: 2/27 04:05 pm Check Earnings Report